148 related articles for article (PubMed ID: 36212077)
1. A mitochondria-targeted nano-platform for pancreatic cancer therapy.
Tan X; Zhu X; Xu D; Shi Y; Wang Z; Cao M; Hu K; Zhao L; Zhao J; Miao M; Zeng H; Wu X
Front Chem; 2022; 10():951434. PubMed ID: 36212077
[TBL] [Abstract][Full Text] [Related]
2. Combination of metronomic administration and target delivery strategies to improve the anti-angiogenic and anti-tumor effects of triptolide.
Cai XJ; Fei WD; Xu YY; Xu H; Yang GY; Cao JW; Ni JJ; Wang Z
Drug Deliv Transl Res; 2020 Feb; 10(1):93-107. PubMed ID: 31418132
[TBL] [Abstract][Full Text] [Related]
3. The use of mitochondrial targeting resveratrol liposomes modified with a dequalinium polyethylene glycol-distearoylphosphatidyl ethanolamine conjugate to induce apoptosis in resistant lung cancer cells.
Wang XX; Li YB; Yao HJ; Ju RJ; Zhang Y; Li RJ; Yu Y; Zhang L; Lu WL
Biomaterials; 2011 Aug; 32(24):5673-87. PubMed ID: 21550109
[TBL] [Abstract][Full Text] [Related]
4. The anticancer efficacy of paclitaxel liposomes modified with mitochondrial targeting conjugate in resistant lung cancer.
Zhou J; Zhao WY; Ma X; Ju RJ; Li XY; Li N; Sun MG; Shi JF; Zhang CX; Lu WL
Biomaterials; 2013 May; 34(14):3626-38. PubMed ID: 23422592
[TBL] [Abstract][Full Text] [Related]
5. Mitochondrial Delivery of an Anticancer Drug Via Systemic Administration Using a Mitochondrial Delivery System That Inhibits the Growth of Drug-Resistant Cancer Engrafted on Mice.
Yamada Y; Munechika R; Satrialdi ; Kubota F; Sato Y; Sakurai Y; Harashima H
J Pharm Sci; 2020 Aug; 109(8):2493-2500. PubMed ID: 32376272
[TBL] [Abstract][Full Text] [Related]
6. Development of targeting lonidamine liposomes that circumvent drug-resistant cancer by acting on mitochondrial signaling pathways.
Li N; Zhang CX; Wang XX; Zhang L; Ma X; Zhou J; Ju RJ; Li XY; Zhao WY; Lu WL
Biomaterials; 2013 Apr; 34(13):3366-80. PubMed ID: 23410681
[TBL] [Abstract][Full Text] [Related]
7. αvβ3 integrin-specific exosomes engineered with cyclopeptide for targeted delivery of triptolide against malignant melanoma.
Gu Y; Du Y; Jiang L; Tang X; Li A; Zhao Y; Lang Y; Liu X; Liu J
J Nanobiotechnology; 2022 Aug; 20(1):384. PubMed ID: 35999612
[TBL] [Abstract][Full Text] [Related]
8. Tumor- and mitochondria-targeted nanoparticles eradicate drug resistant lung cancer through mitochondrial pathway of apoptosis.
Wang H; Zhang F; Wen H; Shi W; Huang Q; Huang Y; Xie J; Li P; Chen J; Qin L; Zhou Y
J Nanobiotechnology; 2020 Jan; 18(1):8. PubMed ID: 31918714
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, characterization and anti-breast cancer activities of stachydrine derivatives.
Zeng H; Xu D; Song Y; Tian S; Qiao J; Li Z; Zhao L; Shi H; Zhou Y; Li S; Luo Y; Li J; Miao M; Wu X
Eur J Med Chem; 2023 Nov; 259():115679. PubMed ID: 37517203
[TBL] [Abstract][Full Text] [Related]
10. Triptolide induces p53-dependent cardiotoxicity through mitochondrial membrane permeabilization in cardiomyocytes.
Xi Y; Wang W; Wang L; Pan J; Cheng Y; Shen F; Huang Z
Toxicol Appl Pharmacol; 2018 Sep; 355():269-285. PubMed ID: 30009776
[TBL] [Abstract][Full Text] [Related]
11. PEGylated liposomes as delivery systems for Gambogenic acid: Characterization and in vitro/in vivo evaluation.
Tang X; Sun J; Ge T; Zhang K; Gui Q; Zhang S; Chen W
Colloids Surf B Biointerfaces; 2018 Dec; 172():26-36. PubMed ID: 30125771
[TBL] [Abstract][Full Text] [Related]
12. Enhanced anticancer efficacy of paclitaxel through multistage tumor-targeting liposomes modified with RGD and KLA peptides.
Sun J; Jiang L; Lin Y; Gerhard EM; Jiang X; Li L; Yang J; Gu Z
Int J Nanomedicine; 2017; 12():1517-1537. PubMed ID: 28280323
[TBL] [Abstract][Full Text] [Related]
13. Chitooligosaccharides Modified Reduction-Sensitive Liposomes: Enhanced Cytoplasmic Drug Delivery and Osteosarcomas-Tumor Inhibition in Animal Models.
Yin X; Chi Y; Guo C; Feng S; Liu J; Sun K; Wu Z
Pharm Res; 2017 Oct; 34(10):2172-2184. PubMed ID: 28726003
[TBL] [Abstract][Full Text] [Related]
14. Overcoming drug-resistant lung cancer by paclitaxel loaded dual-functional liposomes with mitochondria targeting and pH-response.
Jiang L; Li L; He X; Yi Q; He B; Cao J; Pan W; Gu Z
Biomaterials; 2015 Jun; 52():126-39. PubMed ID: 25818419
[TBL] [Abstract][Full Text] [Related]
15. Modulating tumour vascular normalisation using triptolide-loaded NGR-functionalized liposomes for enhanced cancer radiotherapy.
Xu YY; Chen YH; Jin J; Yuan Y; Li JM; Cai XJ; Zhang RY
J Liposome Res; 2023 Sep; 33(3):251-257. PubMed ID: 36601687
[TBL] [Abstract][Full Text] [Related]
16. Triptolide-induced oxidative stress involved with Nrf2 contribute to cardiomyocyte apoptosis through mitochondrial dependent pathways.
Zhou J; Xi C; Wang W; Fu X; Jinqiang L; Qiu Y; Jin J; Xu J; Huang Z
Toxicol Lett; 2014 Nov; 230(3):454-66. PubMed ID: 25169008
[TBL] [Abstract][Full Text] [Related]
17. Synergetic delivery of triptolide and Ce6 with light-activatable liposomes for efficient hepatocellular carcinoma therapy.
Yu L; Wang Z; Mo Z; Zou B; Yang Y; Sun R; Ma W; Yu M; Zhang S; Yu Z
Acta Pharm Sin B; 2021 Jul; 11(7):2004-2015. PubMed ID: 34386334
[TBL] [Abstract][Full Text] [Related]
18. Mitochondrial targeting nanodrugs self-assembled from 9-O-octadecyl substituted berberine derivative for cancer treatment by inducing mitochondrial apoptosis pathways.
Song J; Lin C; Yang X; Xie Y; Hu P; Li H; Zhu W; Hu H
J Control Release; 2019 Jan; 294():27-42. PubMed ID: 30445003
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and tissue distribution study in mice of triptolide-loaded lipid emulsion and accumulation effect on pancreas.
Li X; Mao Y; Li K; Shi T; Yao H; Yao J; Wang S
Drug Deliv; 2016 May; 23(4):1344-54. PubMed ID: 25853479
[TBL] [Abstract][Full Text] [Related]
20. Triptolide-induced hepatotoxicity can be alleviated when combined with Panax notoginseng saponins and Catapol.
Zhou L; Zhou C; Feng Z; Liu Z; Zhu H; Zhou X
J Ethnopharmacol; 2018 Mar; 214():232-239. PubMed ID: 29277608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
